Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, Berkenstock MK, Bermas B, Braaten T, Budde LE, Chokshi S, Crees ZD, Davies M, Deng C, Gesthalter Y, Jain M, Jain P, Jallouk A, Kaffenberger BH, Khalil M, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Prosek J, Reddy S, Reid P, Ryan J, Ryder M, Salman H, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Zucker S, Lyons M, Awotiwon A, Hang L. Thompson JA, et al. Among authors: jain m, jain p. J Natl Compr Canc Netw. 2024 Nov;22(9):582-592. doi: 10.6004/jnccn.2024.0057. J Natl Compr Canc Netw. 2024. PMID: 39536465
Role of immune-checkpoint inhibitors in lung cancer.
Jain P, Jain C, Velcheti V. Jain P, et al. Among authors: jain c. Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750075. doi: 10.1177/1753465817750075. Ther Adv Respir Dis. 2018. PMID: 29385894 Free PMC article. Review.
Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.
Smith RJ Jr, Zollo R, Kalvapudi S, Vedire Y, Pachimatla AG, Petrucci C, Shaller G, Washington D, Rr V, Sass SN, Srinivasan A, Kannisto E, Bawek S, Jain P, Rosario S, Barbi J, Yendamuri S. Smith RJ Jr, et al. Among authors: jain p. J Natl Cancer Inst. 2024 Nov 19:djae295. doi: 10.1093/jnci/djae295. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39560490
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P, Gutierrez Bugarin J, Guha A, Jain C, Patil N, Shen T, Stanevich I, Nikore V, Margolin K, Ernstoff M, Velcheti V, Barnholtz-Sloan J, Dowlati A. Jain P, et al. Among authors: jain c. ESMO Open. 2021 Oct;6(5):100252. doi: 10.1016/j.esmoop.2021.100252. Epub 2021 Aug 27. ESMO Open. 2021. PMID: 34461483 Free PMC article.
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM; COVID-19 and Cancer Consortium. Bakouny Z, et al. JAMA Oncol. 2023 Jan 1;9(1):128-134. doi: 10.1001/jamaoncol.2022.5357. JAMA Oncol. 2023. PMID: 36326731 Free PMC article.
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.
Gulati S, Hsu CY, Shah S, Shah PK, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow DB, Egan PC, Fein J, Flora DB, Friese CR, Fromowitz A, Griffiths EA, Hwang C, Jani C, Joshi M, Khan H, Klein EJ, Heater NK, Koshkin VS, Kwon DH, Labaki C, Latif T, McKay RR, Nagaraj G, Nakasone ES, Nonato T, Polimera HV, Puc M, Razavi P, Ruiz-Garcia E, Saliby RM, Shastri A, Singh SRK, Tagalakis V, Vilar-Compte D, Weissmann LB, Wilkins CR, Wise-Draper TM, Wotman MT, Yoon JJ, Mishra S, Grivas P, Shyr Y, Warner JL, Connors JM, Shah DP, Rosovsky RP; COVID-19 and Cancer Consortium. Gulati S, et al. JAMA Oncol. 2023 Oct 1;9(10):1390-1400. doi: 10.1001/jamaoncol.2023.2934. JAMA Oncol. 2023. PMID: 37589970 Free PMC article.
Afatinib and lung cancer.
Jain P, Khanal R, Sharma A, Yan F, Sharma N. Jain P, et al. Expert Rev Anticancer Ther. 2014 Dec;14(12):1391-406. doi: 10.1586/14737140.2014.983083. Expert Rev Anticancer Ther. 2014. PMID: 25417728 Review.
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Guha A, Jain P, Fradley MG, Lenihan D, Gutierrez JM, Jain C, de Lima M, Barnholtz-Sloan JS, Oliveira GH, Dowlati A, Al-Kindi S. Guha A, et al. Among authors: jain p, jain c. Cancer Med. 2021 Jun;10(12):3862-3872. doi: 10.1002/cam4.3938. Epub 2021 May 13. Cancer Med. 2021. PMID: 33982883 Free PMC article.
3,399 results